ReviewClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
TTD expert consensus on emesis in gastric cancer: evidence-based strategies for prevention and treatment.
Review in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Modulation of the gut microbiota by traditional Chinese medicine to attenuate chemotherapy-induced toxicity in gastric cancer: a review.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Emesis is a common complication in patients with gastric cancer (GC), resulting from both tumor progression and adverse events of antineoplastic therapies. It is estimated that up to 70% of patients experience nausea and vomiting, significantly impacting quality of life. Symptoms can lead to dehydration, malnutrition, fatigue, and emotional disturbances like anxiety and depression. Etiological factors fall into two categories. First, neoplasia-related mechanisms-gastric outlet obstruction, gastroparesis due to autonomic dysfunction, invasion of adjacent structures, presence of peritoneal carcinomatosis or malignant ascites-contribute to gastric emptying disorders. Second, antineoplastic treatments-including chemotherapy, radiotherapy, and targeted therapies-carry an inherent inducing emesis risk and can cause acute, delayed, anticipatory, breakthrough, or refractory emesis. International guidelines from the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), Multinational Association of Supportive Care in Cancer (MASCC), and National Comprehensive Cancer Network (NCCN) recommend combination regimens that include 5-hydroxytryptamine type 3 receptor antagonist (anti-5-HT3), dexamethasone, neurokinin-1 receptor antagonists (anti-NK1), and, occasionally, olanzapine. Prophylaxis should be tailored to the emetic risk of the treatment and the individual characteristics of the patient, like age, sex, and pharmacogenomic factors. Pharmacological strategies should be complemented with non-pharmacological interventions to enhance therapeutic efficacy and alleviate symptoms. This consensus guide from the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) highlights the importance of multidisciplinary and individualized approaches to managing emesis associated with GC. Evidence-based therapeutic algorithms are essential to achieving these goals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.